The Entidade Reguladora Independente da Saúde (ERIS) has issued guidance on how the updated National Medicines List (LNM) affects special import procedures and co-payment arrangements.
The circular, dated 19 November 2026, explains that medicines which have joined the new LNM—approved by Decree-Law 48/2026 of 15 October—are no longer subject to special import procedures. Importers no longer need to obtain a Certificate of Import Authorisation (CAI) or submit a medical declaration of clinical justification to bring these products into the country.
The co-payment regime for medicines must be reviewed and updated within a maximum of 180 days. Until then, co-payment conditions set out in certificates already issued remain in force during the transitional period.
ERIS stated it will monitor implementation of the new LNM to safeguard national supply and patient access to medicines.
Source: Entidade Reguladora Independente da Saúde (ERIS), “ERIS esclarece procedimentos de importação especial de medicamentos após atualização da Lista Nacional de Medicamentos”, 20 November 2026: https://eris.cv/index.php/noticias/1079-eris-esclarece-procedimentos-de-importacao-especial-de-medicamentos-apos-atualizacao-da-lista-nacional-de-medicamentos